Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial

30 August 2026 (14:30 - 14:45)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology